{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:38:11Z","timestamp":1793255891723,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CVIR Endovasc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Transcatheter arterial embolization (TAE) has been widely performed for renal angiomyolipomas (AMLs) as prophylaxis or emergency treatment. On the other hand, mammalian target of rapamycin (mTOR) inhibitors have recently been used for tuberous sclerosis (TSC)-related AMLs, and no comparison between the effectiveness of mTOR inhibitors versus prophylactic selective TAE has yet been performed.<\/jats:p>\n<jats:p>Therefore, the purpose of this study was to evaluate the efficacy of TAE for AML tumor volume reduction and predictors of tumor volume decrease over 50%, with reference to the EXIST-2 trial.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 44 patients who underwent 48 prophylactic embolization procedures for 50 AMLs in a single institution between 2004 and 2018 were included. Indications for TAE of AMLs were tumor size \u22654\u2009cm or aneurysm \u22655\u2009mm in diameter on contrast-enhanced computed tomography (CECT). Microspheres, ethanol, and micro-coils were used as embolic agents. The percentage volume reduction from before TAE to the minimum volume during follow-up after TAE was calculated, and predictors for 50% volume reduction were identified by univariate and multivariate binary logistic regression analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The technical success rate was 100% (50 of 50). No severe acute complications related to the procedure were encountered. Tumor volume reduction of \u226550% was observed in 35\/50 AMLs. There was a significant difference in the rate of tumor volume reduction of 50% between the presence and absence of an aneurysm \u22655\u2009mm and between tumor diameter\u2009\u2265\u200970\u2009mm and\u2009&lt;\u200970\u2009mm on univariate analysis. On multivariate analysis, tumor diameter\u2009&lt;\u200970\u2009mm was the only independent predictor of significant tumor volume reduction after TAE.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Prophylactic selective TAE for AMLs has good tumor-reduction effects, especially for AMLs with tumor diameter\u2009&lt;\u200970\u2009mm.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s42155-020-00179-2","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T04:55:55Z","timestamp":1605934555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of prophylactic selective arterial embolization for renal angiomyolipomas: identifying predictors of 50% volume reduction"],"prefix":"10.1186","volume":"3","author":[{"given":"Hidenari","family":"Hongyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaishu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ujike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"issue":"9869","key":"179_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 381(9869):817\u2013824","journal-title":"Lancet."},{"key":"179_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E et al (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 31:111\u2013119","journal-title":"Nephrol Dial Transplant"},{"issue":"4 Pt 1","key":"179_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2015.07.126","volume":"195","author":"AS Flum","year":"2016","unstructured":"Flum AS, Hamoui N, Said MA et al (2016) Update on the diagnosis and management of renal angiomyolipoma. J Urol 195(4 Pt 1):834\u2013846","journal-title":"J Urol"},{"key":"179_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000475142","volume":"27","author":"Y Fujii","year":"1995","unstructured":"Fujii Y, Ajima J, Oka K et al (1995) Benign renal tumors detected among healthy adults by abdominal ultrasonography. Eur Urol 27:124\u2013127","journal-title":"Eur Urol"},{"key":"179_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/01.ju.0000100100.36354.61","volume":"171","author":"T Harabayashi","year":"2004","unstructured":"Harabayashi T, Shinohara N, Katano H, Nonomura K, Shimizu T, Koyanagi T (2004) Management of renal angiomyolipoma associated with tuberous sclerosis complex. J Urol 171:102\u2013105","journal-title":"J Urol"},{"key":"179_CR6","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0022-5347(17)32286-3","volume":"152","author":"MJ Kennelly","year":"1994","unstructured":"Kennelly MJ, Grossman HB, Cho KJ (1994) Outcome analysis of 42 cases of renal angiomyolipoma. J Urol 152:1988\u20131991","journal-title":"J Urol"},{"key":"179_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.jvir.2017.06.019","volume":"28","author":"O Khalilzadeh","year":"2017","unstructured":"Khalilzadeh O, Baerlocher MO, Shyn PB et al (2017) Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of practice committee. J Vasc Interv Radiol 28:1432\u20131143","journal-title":"J Vasc Interv Radiol"},{"key":"179_CR8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s11255-018-1953-3","volume":"50","author":"L Lin","year":"2018","unstructured":"Lin L, Wang C, Pei R et al (2018) Prophylactic selective arterial embolization for renal angiomyolipomas: efficacy and evaluation of predictive factors of significant shrinkage. Int Urol Nephrol 50:1765\u20131770","journal-title":"Int Urol Nephrol"},{"key":"179_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0022-5347(05)64440-0","volume":"168","author":"CP Nelson","year":"2002","unstructured":"Nelson CP, Sanda MG (2002) Contemporary diagnosis and management of renal angiomyolipoma. J Urol 168:1315\u20131325","journal-title":"J Urol"},{"key":"179_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:255\u2013265","journal-title":"Pediatr Neurol"},{"key":"179_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1051-0443(94)71558-X","volume":"5","author":"MC Soulen","year":"1994","unstructured":"Soulen MC, Faykus MH Jr, Shlansky-Goldberg RD, Wein AJ, Cope C (1994) Elective embolization for prevention of hemorrhage from renal angiomyolipoma. J Vasc Interv Radiol 5:587\u2013591","journal-title":"J Vasc Interv Radiol"},{"key":"179_CR12","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/S0022-5347(17)35895-0","volume":"150","author":"MS Steiner","year":"1993","unstructured":"Steiner MS, Goldman SM, Fishman EK et al (1993) The natural history of renal angiomyolipoma. J Urol 150:1782\u20131786","journal-title":"J Urol"},{"key":"179_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-5347(17)32809-4","volume":"152","author":"JG Van Baal","year":"1994","unstructured":"Van Baal JG, Smith NJ, Keeman JN, Lindhout D, Verhoef S (1994) The evolution of renal angiomyolipoma in patients with tuberous sclerosis. J Urol 152:35\u201338","journal-title":"J Urol"},{"key":"179_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.juro.2011.04.082","volume":"186","author":"JD Villalta","year":"2011","unstructured":"Villalta JD, Sorensen MD, Durack JC et al (2011) Selective arterial embolization of angiomyolipomas: a comparison of smaller and larger embolic agents. J Urol 186:921\u2013927","journal-title":"J Urol"},{"key":"179_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1148\/radiol.2251011477","volume":"225","author":"K Yamakado","year":"2002","unstructured":"Yamakado K, Tanaka N, Nakagawa T et al (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78\u201382","journal-title":"Radiology"}],"container-title":["CVIR Endovascular"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-020-00179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42155-020-00179-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-020-00179-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T04:57:18Z","timestamp":1605934638000},"score":1,"resource":{"primary":{"URL":"https:\/\/CVIRendovasc.springeropen.com\/articles\/10.1186\/s42155-020-00179-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1186\/s42155-020-00179-2","relation":{},"ISSN":["2520-8934"],"issn-type":[{"value":"2520-8934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,21]]},"assertion":[{"value":"7 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the ethics committee of our hospital. Formal consent is not required for this type of study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}